arrow
Y

Yousef Zakharia

Mayo Clinic Comprehensive Cancer Center
H指数:39
被引数:7,502

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

11 Long-Term Follow-Up from the OMNIVORE Trial: Response-Adaptive Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma (NCT03652142)

11 OMNIVORE试验的长期随访:适应性纳武利尤单抗和伊匹木单抗在晚期肾细胞癌中的疗效(NCT03652142)

2026-09-020
OAAI
12 Farnesyl Transferase Inhibitor (FTI) Darlifarnib Combined with Cabozantinib in Renal Cell Carcinoma (RCC): Updated Phase 1a Results from FIT-001

12 法尼基转移酶抑制剂(FTI)达利法尼布与卡博替尼联用治疗肾细胞癌(RCC):FIT-001研究更新后的1a期结果

2026-09-020
OAAI
52 FGD1 Splice Variant in Clear Cell Renal Cell Carcinoma is a Novel Biomarker for Inferior Clinical Outcomes and Development of Brain and Bone Metastases

52 透明细胞肾细胞癌中的FGD1剪接变体是预测不良临床结局和脑骨转移发生的新的生物标志物

2026-09-020
OAAI
Clinical outcomes of HIF-2α inhibition in Von Hippel–Lindau disease: a multicenter real-world study

HIF-2α抑制在Von Hippel–Lindau病中的临床结局:一项多中心真实世界研究

2026-08-180
OAAI
Computed tomography-derived extracellular volume fraction is associated with high-grade recurrence in non-muscle-invasive bladder cancer treated with intravesical gemcitabine and docetaxel

基于计算机断层扫描的细胞外体积分数与非肌层浸润性膀胱癌经膀胱内吉西他滨和多西他赛治疗后的高级别复发相关

2026-05-280
PRE
RESPONSE OF VENOUS TUMOR THROMBI IN RENAL CELL CARCINOMA TO IMMUNE CHECKPOINT INHIBITOR THERAPY: A MULTICENTER RETROSPECTIVE COHORT STUDY

肾细胞癌静脉肿瘤血栓对免疫检查点抑制剂治疗的反应:一项多中心回顾性队列研究

2026-05-010
PRE
ENRICHED YES1 TUMOR EXPRESSION AT THE STROMAL INTERFACE IS ASSOCIATED WITH WORSE OVERALL SURVIVAL IN CLEAR CELL RENAL CELL CARCINOMA WHEN TREATED WITH FIRST-LINE IMMUNE CHECKPOINT BLOCKADE

富集于基质界面的YES1肿瘤表达在接受一线免疫检查点阻断治疗的患者中与透明细胞肾细胞癌较差的总生存期相关

2026-05-010
PRE
FGD1 SPLICE VARIANT IN CLEAR CELL RENAL CELL CARCINOMA IS A NOVEL BIOMARKER FOR INFERIOR CLINICAL OUTCOMES AND DEVELOPMENT OF BRAIN AND BONE METASTASIS

FGD1剪接变体是透明细胞肾细胞癌中预测不良临床结局及脑、骨转移发展的新型生物标志物

2026-05-010
PRE
Epigenetic Modulation, Intratumoral Microbiome, and Immunity in Early-Onset Colorectal Cancer
2025-11-010
OA
Genomic alterations and associated outcomes in patients with PSMA-positive metastatic castration-resistant prostate cancer treated with 177Lu-PSMA-617

PSMA阳性转移性去势抵抗性前列腺癌患者接受177Lu-PSMA-617治疗后的基因组改变及关联结局

2025-11-010
PRE
Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative study

FGFR3突变型晚期尿路上皮癌中,erdafitinib在enfortumab vedotin治疗前或治疗后的疗效:UNITE协作研究的分析

2025-11-010
PRE
Treatment-Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE Study

接受恩沃利单抗维多汀治疗的晚期尿路上皮癌患者中的治疗相关不良事件及关联结局:UNITE研究的分析

2025-10-020
OAAI
FGD1 splice variant as a novel biomarker for inferior clinical outcomes and development of brain and bone metastasis in clear cell renal cell carcinoma

FGD1剪接变异体作为透明细胞肾细胞癌不良临床结局及脑、骨转移发展的新型生物标志物

2025-10-010
OAAI
Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study

恩福妥单抗(Enfortumab Vedotin)在具有不同组织学亚型的晚期尿路上皮癌患者中的疗效:UNITE研究的分析

2025-09-140
PRE
Developing biomarkers and methods of risk stratification: Consensus statements from the International Kidney Cancer Symposium North America 2024 Think Tank

开发生物标志物和风险分层方法:国际肾癌研讨会北美2024年思辨研讨会的共识声明

2025-09-010
PRE